PixarBio Corporation
PXRB
Other OTC0.00
USD
- -
- -
ISIN
US72582G1094
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
- -
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Francis M. Reynolds
- Full Time Employees
- 30
- Sector
- Consumer Cyclical
- Industry
- Personal Products & Services
- Address
- United States of America
- IPO Date
- Jun 27, 2023
- Similar Companies
- Business
- PixarBio Corporation (OTCPK:PXRB) is a clinical-stage immuno-oncology company focused on developing novel cancer immunotherapies; its primary platform centers on personalized neoantigen vaccines that utilize next-generation sequencing and proprietary bioinformatics to target patient-specific tumor mutations; PixarBio also advances oncolytic virus therapies designed to selectively infect and destroy tumor cells while stimulating systemic antitumor immunity; the company's pipeline features lead candidates in early-phase clinical trials, evaluated both as monotherapies and in combination with immune checkpoint inhibitors; PixarBio collaborates with academic centers and contract research organizations for multi-center studies under rigorous protocols. Headquartered in Medford, Massachusetts, the company concentrates operations on the North American market with intentions to expand clinical and regulatory efforts internationally as programs advance; it employs a streamlined model relying on external biotechnology research, clinical development, and regulatory expertise. PixarBio maintains approximately 30 employees and trades on OTC Markets, serving healthcare providers and patients through its innovative approaches to precision oncology. No major recent partnerships, funding rounds, acquisitions, new product launches, or strategic shifts have been publicly reported in the last one to two years.